Cotto at 13:15, 14 May 2024

2024-05-14T13:15:50Z

New page

<noinclude>
This is the "SR Study" form.
To create a page with this form, enter the page name below;
if a page with that name already exists, you will be sent to a form to edit that page.

{{#forminput:form=SR Study}}

</noinclude><includeonly>

=Publication=

{{{for template|Reference}}}
{| class="formtable"
! Publication:
| {{{field|Reference|input type=text|default=?}}}
|}

=Brief summary=
{{{section|Brief summary|level=1}}}

=Search Strategy=
{{{section|Search Strategy|level=1}}}

{{{for template|Search Strategy}}}
{| class="formtable"
! Search period start:
| {{{field|Search period start|input type=date}}}
|-
! Search period end:
| {{{field|Search period end|input type=date}}}
|-
! Number of databases:
| {{{field|Number of databases|input type=text|mandatory|default=-999}}}
|-
! Databases used:
| {{{field|Databases used|input type=textarea|mandatory|default=?}}}
|}

=Study Design=
{{{section|Study Design|level=1}}}

{{{for template|Study Design (SR)}}}
{| class="formtable"
! Meta analysis:
| {{{field|Meta analysis|input type=checkbox}}}
|-
! Type(s) of included studies: {{#info: RCT: randomized controlled trial; CT: controlled trial; SR: systematic review|note}}
| {{{field|Type of included studies|input type=checkboxes|mandatory|default=?}}}
|-
! Number of included studies:
| {{{field|Number of included studies|input type=textarea|default=-999}}}
|-
! Inclusion criteria:
| {{{field|Inclusion criteria|input type=textarea|default=?}}}
|-
! Exclusion criteria:
| {{{field|Exclusion criteria|input type=textarea|default=?}}}
|-
! Number of examined persons:
| {{{field|Number of examined persons|input type=textarea|default=-999}}}
|-
! Overall Drop-out: {{#info: Number of participants who left the study for any reason or did not provide information on every data collection date|note}}
| {{{field|Overall Drop-out|input type=textarea|default=?}}}
|-
! Countries of data collection:
| {{{field|Countries of data collection|input type=text with autocomplete|delimiter=,|values=Afghanistan,Albania,Algeria,Andorra,Angola,Antigua & Deps,Argentina,Armenia,Australia,Austria,Azerbaijan,Bahamas,Bahrain,Bangladesh,Barbados,Belarus,Belgium,Belize,Benin,Bhutan,Bolivia,Bosnia Herzegovina,Botswana,Brazil,Brunei,Bulgaria,Burkina,Burundi,Cambodia,Cameroon,Canada,Cape Verde,Central African Rep,Chad,Chile,China,Colombia,Comoros,Congo,Congo {Democratic Rep},Costa Rica,Croatia,Cuba,Cyprus,Czech Republic,Denmark,Djibouti,Dominica,Dominican Republic,East Timor,Ecuador,Egypt,El Salvador,Equatorial Guinea,Eritrea,Estonia,Ethiopia,Fiji,Finland,France,Gabon,Gambia,Georgia,Germany,Ghana,Greece,Grenada,Guatemala,Guinea,Guinea-Bissau,Guyana,Haiti,Honduras,Hungary,Iceland,India,Indonesia,Iran,Iraq,Ireland {Republic},Israel,Italy,Ivory Coast,Jamaica,Japan,Jordan,Kazakhstan,Kenya,Kiribati,Korea North,Korea South,Kosovo,Kuwait,Kyrgyzstan,Laos,Latvia,Lebanon,Lesotho,Liberia,Libya,Liechtenstein,Lithuania,Luxembourg,Macedonia,Madagascar,Malawi,Malaysia,Maldives,Mali,Malta,Marshall Islands,Mauritania,Mauritius,Mexico,Micronesia,Moldova,Monaco,Mongolia,Montenegro,Morocco,Mozambique,Myanmar,Burma,Namibia,Nauru,Nepal,Netherlands,New Zealand,Nicaragua,Niger,Nigeria,Norway,Oman,Pakistan,Palau,Panama,Papua New Guinea,Paraguay,Peru,Philippines,Poland,Portugal,Qatar,Romania,Russian Federation,Rwanda,St Kitts & Nevis,St Lucia,Saint Vincent & the Grenadines,Samoa,San Marino,Sao Tome & Principe,Saudi Arabia,Senegal,Serbia,Seychelles,Sierra Leone,Singapore,Slovakia,Slovenia,Solomon Islands,Somalia,South Africa,South Sudan,Spain,Sri Lanka,Sudan,Suriname,Swaziland,Sweden,Switzerland,Syria,Taiwan,Tajikistan,Tanzania,Thailand,Togo,Tonga,Trinidad & Tobago,Tunisia,Turkey,Turkmenistan,Tuvalu,Uganda,Ukraine,United Arab Emirates,United Kingdom,United States,Uruguay,Uzbekistan,Vanuatu,Vatican City,Venezuela,Vietnam,Yemen,Zambia,Zimbabwe,NI,?|default=?}}}
|-
! LoE: {{#info: Level of evidence|note}}
| {{{field|LoE|input type=dropdown|mandatory|default=?}}}
|}

=Review characteristics=
{{{section|Review characteristics|level=1}}}

{{{for template|SR Study}}}
{| class="formtable"
! Settings: {{#info: Curative: aims to eliminate a disease or condition, often through surgery, medication, or other interventions; Palliative: focuses on providing relief from symptoms and improving the quality of life for patients, without necessarily targeting the underlying disease|note}}
| {{{field|Setting|input type=checkboxes|mandatory|default=?|delimiter=;|values=?; neo-adjuvant; adjuvant; palliative; NI}}}
|-
! Types of cancer:
| {{{field|Types of cancer|input type=text with autocomplete|mandatory|default=?}}}
|-
! Cancer stages: {{#info: Early Stage: generally refers to cancer that is localized to the area where it started, mostly stages I and II;
Advanced Stage: cancer that has spread beyond its original site, mostly stages III and IV, with stage IV indicating distant metastasis|note}}
| {{{field|Cancer stage|input type=checkboxes|mandatory|default=?}}}
|-
! Specifications on cancer stages:
| {{{field|Cancer stage specification|input type=textarea|default=?}}}
|-
! Comorbidities:
| {{{field|Comorbidity|input type=textarea|default=?}}}
|-
! Cancer therapies:
| {{{field|Current cancer therapy|input type=text with autocomplete|mandatory|default=?}}}
|-
! Specifications on cancer therapies:
| {{{field|Specifications on cancer therapies|input type=textarea|default=?}}}
|-
! Gender:
| {{{field|Gender|input type=radiobutton|mandatory|default=?}}}
|-
! Gender specifications:
| {{{field|Gender specifications|input type=textarea|default=?}}}
|-
! Age groups:
| {{{field|Age groups|input type=checkboxes|values=?, children (0-15), adolescents and young adults (15-39), adults (18+), elderly (65+), NI|default=adults (18+)}}}
|-
! Age groups specification:
| {{{field|Age groups specification|input type=textarea|default=?}}}
|}

=Arms=
{{{section|Arms|level=1}}}

{{{for template|Arm (SR)|multiple}}}
'''Arm type:''' {{#info: Active control: group receives active treatment;
Passive control: for example: treatment as usual, waiting control, no treatment|note}}
{{{field|Arm type|input type=checkboxes|mandatory|default=?}}}

'''Number of studies (arm):''' {{{field|Number of studies (arm)|input type=text|mandatory|default=-999}}}

'''Number of participants (arm):''' {{{field|Number of participants (arm)|input type=textarea|mandatory|default=-999}}}

'''Intervention:''' {{{field|Intervention|input type=textarea|default=?}}}

'''Dosage and regime:''' {{{field|Dosage and regime|input type=textarea|mandatory|default=?}}}

'''Duration in days:''' {{{field|Duration in days|input type=textarea|mandatory|default=?}}}

'''Side Effects / Interactions:''' {{{field|Side Effects / Interactions|input type=textarea|mandatory|default=?}}}

{{{end template}}}

{{{for template|Arm Overview (SR)}}}
{{{end template}}}

=Outcomes=
{{{section|Outcomes|level=1}}}

{{{for template|Outcome (SR)|multiple}}}
'''Outcome name:''' {{{field|Outcome name|input type=text with autocomplete|mandatory|default=?|delimiter=,|values=Anxiety,Anorexia/Cachexia,Appetite,Dermatitis,Depression,Distress,Dysgeusia,Ejection fraction,Sleep disorder (Insomnia),Relaxation,Erectile dysfunction,Menopausal symptoms,Hot flushes,Fatigue,Haematological toxicity,Hand-foot syndrome,Hepatotoxicity,Ileus (intestinal obstruction),Cognitive impairment,Quality of life,Lymphedema,Mucositis,Peripheral neuropathy,Chemotherapy-induced peripheral neuropathy,Neutropenia,Ototoxicity,Pain,Cognitive functioning,Shoulder mobility,Mood/Affect,Stress,Toxicity,Nausea,Vomiting,Emesis,Nausea and Vomiting,CINV (Chemotherapy-induced nausea and vomiting),Well-being,Vaginal atrophy,Wound healing,Xerostomia,Cerebral oedema,OS (Survival),PFS (Progression free survival),DFS (Disease free survival),Recurrence rate,Restoration of bowel function after surgery,Inflammation of the pelvic mucosa (diarrhoea) due to radiotherapy,Inflammation of the oral mucosa (mucositis) due to radiotherapy,Side effects of androgen deprivation /suppression,Weight,Reduction of complication rates,Fatigue,Quality of life,Pain,Survival}}}

'''Outcome specification:''' {{{field|Outcome specification|input type=textarea|default=?}}}

'''Type of measurement:''' {{{field|Type of measurement|input type=text with autocomplete|mandatory|default=?|delimiter=,|values=FAACT (Functional Assessment of Anorexia-Cachexia Therapy),EORTC QLQ-30 (European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire),Weight,NRS (Numeric Rating Scale),NRS (Nutritional Risk Screening),VAS (Visual Analogue Scale),MADRS (Montgomery-Asberg Depression Rating Scale),HADS (Hospital Anxiety and Depression Scale),HFRDIS (Hot Flash Related Daily Interference Scale),HFS (Hot Flush Score),ESAS (Edmonton Symptom Assessment Scale),EORTC QLQ-C15- PAL (European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire - Short form for palliative patients) ,MFI-20 (Multidimensional Fatigue Inventory-20),FACIT (Functional Assessment of Chronic Illness Therapy),CTCAE (Common Terminology Criteria of Adverse Events),Postoperative morbidity/ complications (classification according to Clavien-Dindo),PHLF (post hepatectomy liver failure),ASAT (Auditory Sustained Attention Test),AQoL-8D (Assessment of Quality of Life),FACT-G (Functional Assessment of Cancer Therapy - General),SF-36 (Short Form-36 Health Survey),WHO-Scale,SPPB (Short Physical Performance Battery),BIA (Bioelectrical impedance analysis) ,Physical functioning (grip strength, 6 minute walk, leg extension),FACT-Taxane (Functional Assessment of Cancer Therapy –Taxane),BPI-SF (Brief Pain Inventory - Short Form),MAT (Multinational Association of Supportive Care in Cancer -Antiemesis Tool),FLIE (Functional Living Index for Emesis),Genitourinary atrophy self-assessment tool,pH-value,VMI (Vaginal Maturation Index),QoR-40 (Quality of Recovery-40 Questionnaire),Wound volume,BFI,QLQ-C30,VAS}}}

'''Results during intervention:''' {{{field|Results during intervention|input type=textarea|mandatory|default=?}}}
'''Results after intervention:''' {{{field|Results after intervention|input type=textarea|mandatory|default=?}}}
{{{end template}}}

{{{for template|Outcome Overview (SR)}}}
{{{end template}}}

=Quality Assessment=
{{{section|Quality Assessment|level=1}}}

{{{for template|Quality Assessment}}}
{| class="formtable"
! Author's Quality Assessment of Included Studies {{#info: The methodological evaluation of the included studies was carried out by the authors of the publication.|note}}
| {{{field|Author's Quality Assessment of Included Studies|input type=textarea|default=?}}}
|-
! RoB assessment with AMSTAR 2 tool: Overall confidence in review results {{#info:Risk of Bias|note}}
| {{{field|Overall confidence in the results of the review|input type=radiobutton|mandatory|default=?}}}
|-
! Specifications (AMSTAR 2 tool)
| {{{field|Specifications concerning AMSTAR 2 tool|input type=textarea|default=?}}}
|-
! Further points on quality assessment
| {{{field|Further points on quality assessment|input type=textarea|default=?}}}
|}

=Funding and Conflicts of Interest=
{{{section|Funding and Conflicts of Interest|level=1}}}

{{{for template|Funding and Conflicts of Interest}}}
{| class="formtable"
! Funding:
| {{{field|Funding|input type=textarea|default=?}}}
|-
! Conflicts of Interest:
| {{{field|Conflicts of Interest|input type=textarea|default=?}}}
|}
{{{end template}}}

=Additional Notes=
{{{section|Additional Notes|level=1}}}

</includeonly>

Form:SR Study - Revision history

Cotto at 13:15, 14 May 2024